Last $266.88 USD
Change Today +7.13 / 2.74%
Volume 4.2M
ACT On Other Exchanges
Symbol
Exchange
Berlin
New York
Mexico
As of 4:15 PM 11/24/14 All times are local (Market data is delayed by at least 15 minutes).

actavis plc (ACT) Snapshot

Open
$261.28
Previous Close
$259.75
Day High
$268.34
Day Low
$261.06
52 Week High
11/19/14 - $270.34
52 Week Low
12/17/13 - $156.40
Market Cap
70.7B
Average Volume 10 Days
5.8M
EPS TTM
$5.09
Shares Outstanding
265.1M
EX-Date
--
P/E TM
52.4x
Dividend
--
Dividend Yield
--
Current Stock Chart for ACTAVIS PLC (ACT)

actavis plc (ACT) Details

Actavis plc, an integrated specialty pharmaceutical company, is engaged in the development, manufacture, marketing, sale, and distribution of pharmaceutical products in the Americas, Europe, the Middle East, Africa, Australia, and the Asia Pacific. It operates in three segments: Actavis Pharma, Actavis Specialty Brands, and Anda Distribution. The Actavis Pharma segment provides generic, branded generic, and over-the-counter (OTC) pharmaceutical products. This segment sells generic prescription products primarily under the Watson Laboratories, Watson Pharma, and Actavis Pharma labels; and OTC generic products under private label. The Actavis Specialty Brands segment offers patent-protected products and trademarked off-patent products, which are marketed as branded pharmaceutical products to physicians, specifically urologists, obstetricians, dermatologists, gastroenterologists, and gynecologists. The Anda Distribution segment primarily distributes generic and selected brand pharmaceutical products, vaccines, injectables, and OTC medicines to independent pharmacies, and to alternate care providers comprising hospitals, nursing homes, and mail order pharmacies, as well as to pharmacy chains, physicians’ offices, and buying groups. The company also develops and out-licenses generic pharmaceutical products primarily in Europe through its third-party business; and provides products in women's health, urology, gastroenterology, and dermatology therapeutic categories. The company has a collaboration agreement with Amgen, Inc. for the development and commercialization of various oncology antibody biosimilar medicines; and a collaboration agreement with Hanmi Pharm. Co. Ltd. to develop Hyalrheuma, a hyaluronic acid injection for arthritis pain treatment. Actavis plc was founded in 1983 and is headquartered in Parsippany, New Jersey.

19,200 Employees
Last Reported Date: 02/25/14
Founded in 1983

actavis plc (ACT) Top Compensated Officers

Executive Chairman
Total Annual Compensation: $2.6M
Chief Financial Officer of Global
Total Annual Compensation: $557.3K
Chief Operating Officer
Total Annual Compensation: $639.5K
Executive Vice President of Commercial - Nort...
Total Annual Compensation: $557.7K
Compensation as of Fiscal Year 2013.

actavis plc (ACT) Key Developments

Actavis plc, Allergan Inc. - M&A Call

To discuss the acquisition of Allergan by Actavis

Actavis plc Presents at 2014 Debt Capital Markets and Derivatives Conference, Nov-20-2014 10:15 AM

Actavis plc Presents at 2014 Debt Capital Markets and Derivatives Conference, Nov-20-2014 10:15 AM. Venue: The Plaza Hotel, Fifth Avenue at Central Park South, New York, New York, United States. Speakers: Stephen Kaufhold, Senior Vice President, Treasurer.

Actavis plc Announces FDA Acceptance of sNDA for SAPHRIS(R) (asenapine) for the Treatment of Bipolar I Disorder in Pediatric Patients

Actavis plc announced that the U.S. Food and Drug Administration (FDA) has accepted for filing Actavis' Supplemental New Drug Application (sNDA) for SAPHRIS(R) (asenapine) for the acute treatment of manic or mixed episodes associated with bipolar I disorder in pediatric patients 10 to 17 years of age. Actavis' sNDA for SAPHRIS has been granted priority review status by the FDA. Actavis expects the Prescription Drug User Fee Act (PDUFA) date to be in First Quarter 2015. The sNDA submission for asenapine is based on the results of a 3-week monotherapy trial in 403 pediatric patients (10 to 17 years of age), of whom 302 received asenapine. In the trial, asenapine was shown to be statistically superior to placebo in the reductions of both the Young Mania Rating Scale (YMRS) total score and Clinical Global Impression-Bipolar (CGI-BP) score at fixed doses of 2.5 mg, 5 mg and 10 mg twice daily. The most commonly observed adverse reactions (incidence >= 5% and at least twice that for placebo) were somnolence, dizziness, dysgeusia, oral hypoesthesia, oral paresthesia, nausea, increased appetite, fatigue and increased weight.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ACT:US $266.88 USD +7.13

ACT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Abbott Laboratories $44.32 USD +0.51
Allergan Inc/United States $211.81 USD +2.72
Covidien PLC $99.36 USD +0.92
Eli Lilly & Co $66.93 USD -0.43
Valeant Pharmaceuticals International Inc C$161.02 CAD -2.36
View Industry Companies
 

Industry Analysis

ACT

Industry Average

Valuation ACT Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 5.8x
Price/Book 2.4x
Price/Cash Flow 64.8x
TEV/Sales 4.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ACTAVIS PLC, please visit www.actavis.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.